19:28 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Huntington's disease (HD) Cell culture studies suggest promoting the expression of ATF4 and CTH could help treat HD. In a mouse striatal cell line expressing mutant HTT and cultured under HD-associated low cysteine conditions,...
19:24 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Diabetic neuropathy Rat studies suggest activating the CTH pathway could help treat diabetic neuropathy. In a rat model of diabetic neuropathy, a tool compound CTH activator or sodium hydrosulfide -- a cell signaling molecule...
19:32 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; breast cancer Patient sample, cell culture and mouse studies suggest inhibiting NFS1 could help treat lung cancer and lung metastases of breast cancer under oxidative stress. In tissue samples from lung cancer...
20:02 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic lymphocytic leukemia; breast cancer; prostate cancer Patient samples, cell culture and mouse studies suggest an engineered CTH variant could help treat CLL, breast cancer and prostate cancer. Combinatorial mutagenesis of the active site...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

Cynapsus, Sumitomo Dainippon deal

Sumitomo’s Sunovion Pharmaceuticals Inc. unit completed its acquisition of Cynapsus for $40.50 per share in cash (see BioCentury, Sept. 5). Cynapsus Therapeutics Inc. (TSX:CTH;NASDAQ:CYNA), Toronto, Ontario  Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan  Business:...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cystathionine γ-lyase (CTH)

Cardiovascular disease INDICATION: Hypertension Mouse and rat studies suggest inhibiting CTH could help treat sleep apnea-induced hypertension. In a mouse model of sleep apnea-induced hypertension, CTH knockout decreased blood pressure and plasma levels of hypertension...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Cynapsus, Sumitomo Dainippon deal

Sumitomo’s Sunovion Pharmaceuticals Inc. unit will acquire Cynapsus for $40.50 per share in a cash deal the companies say values Cynapsus at about $624 million. The price is a 121% premium to Cynapsus’ close of...
07:00 , Aug 31, 2016 |  BC Extra  |  Top Story

Sunovion to acquire Cynapsus for $624M

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) announced after market close Wednesday that it will acquire neurology company Cynapsus Therapeutics Inc. (TSX:CTH; NASDAQ:CYNA) for about $624 million in cash. Sunovion...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

APL-130277: Preliminary Phase III data

Preliminary data from 92 evaluable PD patients in the open-label, dose-escalation portion of the U.S. Phase III CTH-300 trial showed that sublingual APL-130227 improved mean MDS-UPDRS Part III score from baseline to 30 and 90...
07:00 , Jul 19, 2016 |  BC Extra  |  Clinical News

Cynapsus reports early Phase III data for PD candidate

Cynapsus Therapeutics Inc. (TSX:CTH; NASDAQ:CYNA) reported data from the open-label, dose-escalation portion of the Phase III CTH-300 study evaluating APL-130277 to treat "off" episodes in patients with Parkinson's disease (PD). In 92 evaluable PD patients,...